(Q38248947)

1 September 2017

1 reference

title

Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine (English)

1 reference

1 September 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Laurence Baril

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Maria-Genalin Angelo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Sylvia Taylor

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Fernanda Tavares Da Silva

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Felix Arellano

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Marie-Pierre David

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Gary Dubin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Dominique Rosillon

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

14 September 2014

1 reference

Expert Review of Vaccines

1 September 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

1297-1306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25219284%20AND%20SRC:MED&resulttype=core&format=json

Vaccine effects and impact of vaccination programmes in post-licensure studies

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Evaluating the impact of human papillomavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

A review of clinical trials of human papillomavirus prophylactic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Safety of human papillomavirus vaccines: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Cervical and anal HPV infections in HIV positive women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Assessing the relationship between HIV infection and cervical cancer in Côte d'Ivoire: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Model-based estimates of long-term persistence of induced HPV antibodies: a flexible subject-specific approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Effectiveness of preventive human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

The safety evaluation of adjuvants during vaccine development: the AS04 experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.959931